Join to View Full Profile
200 1st Street, SWRochester, MN 55905
Dr. Abdelmalek is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Manal Abdelmalek is a gastroenterologist based in Rochester, MN, with subspecialties in hepatology and liver transplantation. She graduated from the University of Missouri Kansas City School of Medicine in 1992 and completed her Internal Medicine residency and Gastroenterology/Hepatology fellowship at Mayo Clinic, Rochester, Minnesota. Her expertise includes liver cirrhosis and metabolic-associated steatotic liver disease. Dr. Abdelmalek has a number of publications on topics including risk factors for fibrosis progression, diagnosis, management and treatment of metabolic dysfunction associated steatotic liver disease and cirrhosis in liver health. She is also actively involved in federal funded and industry sponsored clinical trials in the treatment of MASLD/MASH and cirrhosis.
Education & Training
University of Missouri Kansas City School of MedicineClass of 1992
Certifications & Licensure
AZ State Medical License 1996 - Present
MN State Medical License 2022 - 2025
NC State Medical License 2006 - 2022
FL State Medical License 1998 - 2011
American Board of Internal Medicine Gastroenterology- American Board of Internal Medicine Transplant Hepatology
Clinical Trials
- Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis Start of enrollment: 2023 Jan 23
Roles: Contact
- Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study Start of enrollment: 2021 May 11
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial ...Wee Han Ng, Yee Hui Yeo, Hyunseok Kim, Ekihiro Seki, Jonathan Rees
Hepatology. 2025-04-02 - 1 citationsOsteopontin Promotes Cholangiocyte Secretion of Chemokines to Support Macrophage Recruitment and Fibrosis in MASH.Jason D Coombes, Paul P Manka, Marzena Swiderska-Syn, Danielle T Vannan, Antonio Riva
Liver International. 2025-04-01 - Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunction.Kuo Du, David S Umbaugh, Wang Liuyang, Ji Hye Jun, Rajesh K Dutta
Nature Communications. 2025-03-28
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
